ICI treatment has been approved for lung cancer, but it has been reported that ICI treatments are less beneficial in EGFR‐mutated NSCLC, and patients with EGFR‐mutated tumors have been excluded from most clinical studies. Here, EGFR is linked to lung carcinoma.